Skip to main content
    1. Home

    • UCB Medicines: Clinical Studies and Scientific Research Publication

    Publications

    This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

    Select product(s):
    Select topic(s):
    Phase:

    *Includes seizure clusters and acute or prolonged seizures

    164 result(s)

    phase 2

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase 2b, randomized, controlled trial

    Wim Van Paesschen, Edouard Hirsch, Martin Johnson et al.  July 19, 2012
    pre clinical

    BRIVIACT® (brivaracetam) CV

    View

    Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse, and human brain: relationship to anti-convulsant properties

    Michel Gillard, Bruno Fuks, Karine Leclercq et al.  May 08, 2011
    phase 2

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial 

    J A French, C Costantini, A Brodsky et al.  June 30, 2010
    None

    None

    Seizure Emergencies
    View

    Opportunities for and Challenges of Pulmonary Drug Delivery in the Management of Acute Exacerbations of CNS Disorders

    Kamil Detyniecki, Adam Strzelczyk, Robert Roebling et al.